Nuvectis Pharma reduces ATM capacity to $5M and suspends sales under Leerink agreement

Nuvectis Pharma, Inc.

On June 29, 2026, Nuvectis lowered the amount available for sale under the Sales Agreement Prospectus to $5 million.
The company is suspending the Sales Agreement Prospectus and will not sell any shares until a new prospectus or registration statement is filed.
The Sales Agreement with Leerink Partners LLC remains in full force and effect; only the current offering is paused.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.